GlassScriptPhysician profile
Joseph M Newmark
NPI 1902939317
$8,781.46
in general payments reported to CMS, 2019-2025
34 companies · $675 in 2025
The $675 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,453 · 2020: $1,159 · 2021: $1,186 · 2022: $1,273 · 2023: $1,315 · 2024: $720 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.06 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,332.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $789.74 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $780.65 | 2019-2025 | Ilumya, Winlevi |
| Lilly USA, LLC | $662.44 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $632.99 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $563.89 | 2019-2023 | Targretin, Siliq |
| Janssen Biotech, INC. | $550.90 | 2019-2025 | Tremfya |
| Genzyme Corporation | $447.95 | 2019-2024 | |
| Incyte Corporation | $422.72 | 2022-2025 | Opzelura |
| Amgen INC. | $312.80 | 2019-2024 | Otezla |
| Galderma Laboratories, L.P. | $296.74 | 2019-2024 | Aklief |
| Ucb, INC. | $272.57 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $215.42 | 2019 | |
| Verrica Pharmaceuticals INC. | $183.68 | 2023 | Ycanth |
| Celgene Corporation | $177.93 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $124.61 | 2019-2021 | |
| Leo Pharma INC. | $119.78 | 2019-2025 | Anzupgo, Adbry |
| Allergan, INC. | $109.73 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $93.22 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $76.38 | 2021-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $76.09 | 2022-2023 | Sotyktu |
| Biofrontera INC. | $73.20 | 2019-2025 | |
| Organogenesis INC. | $72.75 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.96 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $68.10 | 2022-2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $45.53 | 2019 | |
| Prugen, INC. Pharmaceuticals | $42.09 | 2019 | |
| Dusa Pharmaceuticals, INC. | $41.59 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $34.30 | 2019-2023 | Valchlor |
| Blueprint Medicines Corporation | $27.45 | 2022 | |
| Dermira, INC. | $20.00 | 2020 | |
| Lnhc, INC | $15.00 | 2025 | Zelsuvmi |
| Aclaris Therapeutics, INC. | $14.47 | 2019 | |
| Arcutis Biotherapeutics, INC. | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Newmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.